The Leukemia & Lymphoma Society (LLS) announced today the first pediatric patient has received treatment in a new subtrial of its Pediatric Acute Leukemia (PedAL) Master Clinical Trial (NCT04726241).

Mark Litzow, MD, discusses the challenges of using immunotherapy for the treatment of acute lymphoblastic leukemia.

Pausing treatment during vaccination did not improve immunity in patients with chronic lymphocytic leukemia and should not be ...

US drug maker AbbVie has launched its key leukemia drug, Venetoclax, in India, marking its entry into the country's oncology ...

Through the launch of Venetoclax for the treatment of both Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL ...

AbbVie expands global oncology footprint in India with launch of Venetoclax: Our Bureau, Bengaluru Monday, April 21, 2025, 16:40 Hrs [IST] AbbVie, a global biopharmaceutical major ...

This is the first CSCO Guidelines recommendation for lisaftoclax (APG-2575), making it the only China-developed Bcl-2 inhibitor recommended in the CSCO Guidelines. This marks a milestone achieved by ...

American pharmaceutical company AbbVie has marked its entry into the Indian cancer drugs segment with Venetoclax used to ...

A 25-year-old athletic woman dies of a rare bone cancer less than a year after her condition of constant back pain was ...

As a marker of minimal residual disease in B-cell acute lymphoblastic leukemia (B-ALL), CD58 has been reported in B-ALL at diagnosis and short-term follow-ups after standard chemotherapies. However, ...